BioWorld

May 20, 2009

Elixir Inks $500M Novartis Option Deal and Closes $12M Financing

Elixir Pharmaceuticals Inc. signed a potential $500 million deal giving Novartis AG the option either to exclusively license worldwide rights to Elixir's ghrelin antagonist program for diabetes or to acquire the biotech outright. (BioWorld Today) Read More

Santhera Shares Plunge as Ataxia Trial Misses Goal

Strategic vs. Financial Backers: Balance Tricky but Worthwhile

Biomarker Integration Necessary but Complex for Drug Discovery

Clarity, Due Diligence Vital in Cross-Border Alliances

HIV/AIDS Work Facing Cash, Resistance Hurdles and More

Hamburg Wins Senate Confirmation as FDA Chief

Other News To Note

Financings Roundup

Clinic Roundup

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld

Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...

3D rendering of skin cells and elastin with collagen layer

First-in-class pan-inflammasome blocker for hidradenitis suppurativa

BioWorld Science

Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.

Illustration of cancer cell in crosshairs being destroyed

RX-10616 improves radiotherapy efficacy in HNSCC

BioWorld Science

Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...

CROI 2026: Neurodegeneration, the challenge of aging with HIV

BioWorld

Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...